Letters: No reason to stop scrips for anticholinergics

GP reports a study by Singh (JAMA 2008; 300: 1,439-50) on anticholinergic inhalers and CVD risk (GP, 26 September).

The study found no causal link between anticholinergic inhalers and CVD, but an association. The justification for the study came from the finding of a previous meta-analysis reported by the FDA which found that tiotropium was associated with an increased risk of stroke.

No association was found with stroke in the new study by Singh et al but, instead, a different set of associations was reported.

In our view, the Singh study has several methodological problems including double counting patients, comparing tiotropium to both active treatments and placebos and failing to account for increased drop-outs in the placebo arms as this resulted in a smaller risk of adverse events.

The findings of an increased risk of cardiovascular events are interesting, and merit further consideration, but are not a reason to change prescribing. The results of the UPLIFT study to be released this month may clarify the safety profile of tiotropium.

We believe Dr Yoon's comments in your article are completely inappropriate. GPs should not change the way they prescribe anticholinergic inhalers on the basis of this single study unless advised by independent bodies. There is no clinical rationale to prescribe anticholinergics for short-term use - they are to treat symptoms and prevent exacerbations of a long-term progressive condition.

Long-term benefits of anticholinergic inhalers have been demonstrated and are reported in UK national and all international guidelines. Dr Yoon's recommendations to GPs on the basis of his single study will cause unnecessary distress to patients and confusion to clinicians.

GPs should allow time for the findings to be considered in the light of other scientific data and reach a calm objective conclusion before they change their prescribing habits.

Professor David Price, professor of primary care respiratory medicine, Aberdeen University; Dr Rupert Jones, GP in Plymouth; Dr Dermot Ryan, GP in Loughborough; Dr Mike Thomas, GP in Gloucestershire; Dr Daryl Freeman, GP in Norfolk; Dr John Haughney, GP in Scotland.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

Viewpoint: Latest government white paper is missed opportunity to reform the GMC

Viewpoint: Latest government white paper is missed opportunity to reform the GMC

The government must not lose sight of promises to reform professional regulation...

UK COVID-19 vaccination programme tracker

UK COVID-19 vaccination programme tracker

GPs across the UK are playing a leading role in the largest-ever NHS vaccination...

Locum GPs half as likely as partners to have both COVID-19 jabs by end of February

Locum GPs half as likely as partners to have both COVID-19 jabs by end of February

Locum GPs were half as likely as GP partners to have received two doses of COVID-19...

One in six doctors report COVID-19 vaccine sites disrupted by delivery failures

One in six doctors report COVID-19 vaccine sites disrupted by delivery failures

One in six doctors say local vaccination sites have been forced to rearrange sessions...

Planned 1% NHS pay rise threatens 'terrible impact on patient care', unions warn

Planned 1% NHS pay rise threatens 'terrible impact on patient care', unions warn

Government plans to increase NHS staff pay by just 1% for 2021/22 will damage patient...

What do we now know about the effectiveness of the COVID-19 vaccines?

What do we now know about the effectiveness of the COVID-19 vaccines?

As real world data about the impact of the Pfizer/BioNTech and Oxford/AstraZenca...